Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Emerging Concepts on the Role of Immunotherapy in NSCLC

February 20th 2023

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.

Data from Additional Clinical Studies on Tumor-Infiltrating Lymphocyte Therapy

February 16th 2023

Shared insight from Amod Sarnaik, MD, and Krishna Komanduri, MD, on the halted DELTA-1 clinical trial of ITIL-168 in melanoma, followed by a focused discussion of SITC 2022 data on emerging TIL design and manufacturing strategies.

Results From the C-144-01 Trial and Potential Impact on Clinical Practice

February 16th 2023

Expert perspectives on results from C-144-01, which utilized the TIL therapy lifileucel in the setting of metastatic melanoma, and situations in which the regimen might be used in clinical practice.

Neoadjuvant Nivolumab Provides Sustained Efficacy in Resected NSCLC

February 15th 2023

Treatment with neoadjuvant nivolumab led to encouraging 5-year recurrence-free survival and overall survival rates compared with historical outcomes in patients with non–small cell lung cancer who underwent surgical resection.

Traveling Through the Lung Cancer Treatment Paradigm: Biomarker Guidance in NSCLC

February 15th 2023

In this second episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the need for additional circulating biomarkers beyond PD-L1 in non–small cell lung cancer.

Neoadjuvant Therapy and Other Emerging Therapies in Early Stage NSCLC

February 14th 2023

Experts discuss the role of neoadjuvant therapy and other emerging therapies in the treatment of early-stage NSCLC.

Treatment Approach for Patients With Stage II-IIIA NSCLC

February 14th 2023

Jaspal Singh, MD, MHS, shares insights on treatment strategies for patients with stage II-IIIA NSCLC.

Future Perspectives in Biomarker Testing and Targeted Therapy in NSCLC

February 13th 2023

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

NSCLC: Discussing Molecular Biomarkers and Treatment Decisions with Patients

February 13th 2023

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Multifaceted Approach Remains a Linchpin for Stage IIIB NSCLC Therapy

February 10th 2023

Although emerging strategies are expanding options for treating patients with early-stage non–small cell lung cancer, stage IIIB disease continues to pose challenges. A multimodality approach may help overcome current barriers to care.

Herbst Highlights the Implications of the FDA Approval of Adjuvant Pembrolizumab in NSCLC

February 9th 2023

Roy S. Herbst, MD, PhD, discussed the data that supported the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer, highlighted the implications of the approval for the paradigm, and outlined further research opportunities.

Tumor-Infiltrating Lymphocyte Therapy: Clinical Data on Biologic Activity

February 9th 2023

A focused discussion on clinical trial data presented at SITC 2022 elucidating the biologic activity of tumor-infiltrating lymphocyte therapies.

Clinical Experience With TIL Therapy for Solid Tumors

February 9th 2023

Amod Sarnaik, MD, and Krishna Komanduri, MD, share their clinical experience with, and practical advice on, tumor-infiltrating lymphocyte therapy for their patients with solid tumors.

Traveling Through the Lung Cancer Treatment Paradigm: Moving Cellular Therapies Across Settings

February 8th 2023

In this first episode of OncChats: Traveling Through the Lung Cancer Treatment Paradigm, Aaron Franke, MD, discusses the exploration of cellular therapies in non–small cell lung cancer.

Immunotherapy Must Become More Precise and Personalized in Lung Cancer

February 7th 2023

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.

Dr. Liu on the Use of MET-targeted Agents in EGFR-mutant NSCLC

February 7th 2023

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

Patient Profile 2: Former Smoker Diagnosed With NSCLC

February 7th 2023

David H. Harpole Jr, MD, presents a case of a former smoker diagnosed with NSCLC, and David Spigel, MD, offers his initial impressions.

Choosing Appropriate Patients for Surgical Resection in NSCLC

February 7th 2023

An expert panel shares perspectives on how to choose the appropriate patients with non-small cell lung cancer for lung resection.

Rising Standards in Regulatory Decisions Highlight Challenges in Drug Development in Lung Cancer

February 6th 2023

If the FDA’s Oncologic Drugs Advisory Committee meeting held on February 10, 2022, was any indication, the days of applying foreign single country or region data to support regulatory approval are gone; instead, regulatory decisions are headed toward the need for regional consistency through multiregional clinical trials, which could help the United States overcome the persistent underrepresentation of racial and ethnic minorities in drug development.

Dr. Park on Determining Treatment Approaches in NSCLC

February 6th 2023

Henry S. Park, MD, MPH, discusses key considerations when selecting an optimal treatment approach for patients with stage II and III non–small cell lung cancer.